JP2017516833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516833A5 JP2017516833A5 JP2016571240A JP2016571240A JP2017516833A5 JP 2017516833 A5 JP2017516833 A5 JP 2017516833A5 JP 2016571240 A JP2016571240 A JP 2016571240A JP 2016571240 A JP2016571240 A JP 2016571240A JP 2017516833 A5 JP2017516833 A5 JP 2017516833A5
- Authority
- JP
- Japan
- Prior art keywords
- linear
- branched
- alkenyl
- pharmaceutically acceptable
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims 6
- 235000020956 nicotinamide riboside Nutrition 0.000 claims 6
- 239000011618 nicotinamide riboside Substances 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 230000000699 topical Effects 0.000 claims 3
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 2
- 208000006641 Skin Disease Diseases 0.000 claims 2
- 125000005466 alkylenyl group Chemical group 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 claims 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 claims 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- MHPUGCYGQWGLJL-UHFFFAOYSA-M 5-methylhexanoate Chemical compound CC(C)CCCC([O-])=O MHPUGCYGQWGLJL-UHFFFAOYSA-M 0.000 claims 1
- OEOIWYCWCDBOPA-UHFFFAOYSA-M 6-methylheptanoate Chemical compound CC(C)CCCCC([O-])=O OEOIWYCWCDBOPA-UHFFFAOYSA-M 0.000 claims 1
- XZOYHFBNQHPJRQ-UHFFFAOYSA-M 7-methyloctanoate Chemical compound CC(C)CCCCCC([O-])=O XZOYHFBNQHPJRQ-UHFFFAOYSA-M 0.000 claims 1
- 229940035676 ANALGESICS Drugs 0.000 claims 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 229940009098 Aspartate Drugs 0.000 claims 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 229940001447 Lactate Drugs 0.000 claims 1
- 210000004400 Mucous Membrane Anatomy 0.000 claims 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N Nicotinamide adenine dinucleotide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims 1
- 229940049964 Oleate Drugs 0.000 claims 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N Oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims 1
- 108009000578 Oxidative Stress Proteins 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 229940029983 VITAMINS Drugs 0.000 claims 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000000202 analgesic Effects 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000000111 anti-oxidant Effects 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 229940077388 benzenesulfonate Drugs 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M caprate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 claims 1
- 229940050411 fumarate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229940097042 glucuronate Drugs 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-L glutarate(2-) Chemical compound [O-]C(=O)CCCC([O-])=O JFCQEDHGNNZCLN-UHFFFAOYSA-L 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 claims 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 1
- 229940070765 laurate Drugs 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 229950006238 nadide Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- KCXFHTAICRTXLI-UHFFFAOYSA-M propane-1-sulfonate Chemical compound CCCS([O-])(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-M 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 229940116351 sebacate Drugs 0.000 claims 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 claims 1
- 229940086735 succinate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000000475 sunscreen Effects 0.000 claims 1
- 239000000516 sunscreening agent Substances 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 claims 1
- 229940070710 valerate Drugs 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamins Natural products 0.000 claims 1
Claims (14)
- 下記構造式（Ｉ）もしくは（ＩＩ）により表される立体異性体的に純粋な化合物またはその薬学的に許容可能な塩：
Ｒ１は、−Ｃ（＝Ｏ）−（Ｃ ４ −Ｃ１８直鎖もしくは分岐）アルキルまたは−Ｃ（＝Ｏ）−（Ｃ ４ −Ｃ１８直鎖もしくは分岐）アルケニルであり、
各Ｒ２ は水素である］。 - 化合物が下記から選択される、請求項１に記載の立体異性体的に純粋な化合物：
- 下記構造式（Ｉ）もしくは（ＩＩ）により表される立体異性体的に純粋な化合物またはその薬学的に許容可能な塩：
Ｒ １ が−Ｃ（＝Ｏ）−Ｘ−（Ｃ １１ −Ｃ １８ 直鎖もしくは分岐）アルキルまたは−Ｃ（＝Ｏ）−Ｘ−（Ｃ １１ −Ｃ １８ 直鎖もしくは分岐）アルケニルであり、
各Ｒ ２ は−Ｃ（＝Ｏ）−Ｘ−（Ｃ １１ −Ｃ １８ 直鎖もしくは分岐）アルキルまたは−Ｃ（＝Ｏ）−Ｘ−（Ｃ １１ −Ｃ １８ 直鎖もしくは分岐）アルケニルであり、かつ
Ｘは共有結合またはＯである）。 - Ｒ１ および／またはＲ ２ が、基Ｃ１１、Ｃ１２、Ｃ１３、Ｃ１４、Ｃ１５、Ｃ１６、Ｃ１７、およびＣ１８から選択される直鎖または分岐アルキルまたはアルケニルを含んでなる、請求項３に記載の立体異性体的に純粋な化合物。
- 下記構造式（Ｉ）もしくは（ＩＩ）により表される立体異性体的に純粋でない化合物またはその薬学的に許容可能な塩：
Ｒ １ が−Ｃ（＝Ｏ）−Ｘ−（Ｃ １１ −Ｃ １８ 直鎖もしくは分岐）アルキルまたは−Ｃ（＝Ｏ）−Ｘ−（Ｃ １１ −Ｃ １８ 直鎖もしくは分岐）アルケニルであり、
各Ｒ ２ は−Ｃ（＝Ｏ）−Ｘ−（Ｃ １１ −Ｃ １８ 直鎖もしくは分岐）アルキルまたは−Ｃ（＝Ｏ）−Ｘ−（Ｃ １１ −Ｃ １８ 直鎖もしくは分岐）アルケニルであり、かつ
Ｘは共有結合またはＯである）。 - Ｒ １ および／またはＲ ２ が、基Ｃ １１ 、Ｃ １２ 、Ｃ １３ 、Ｃ １４ 、Ｃ １５ 、Ｃ １６、 Ｃ １７ 、およびＣ １８ から選択される直鎖または分岐アルキルまたはアルケニルを含んでなる、請求項５に記載の立体異性体的に純粋でない化合物。
- 塩素物、臭素物、ヨウ素物、ナイトレート、サルフェート、サルファイト、ホスフェート、カーボネート、ビカーボネート、メタンスルホネート（メシレート）、エタンスルホネート、プロパンスルホネート、ベンゼンスルホネート（ベンジレート）、パラ−トルエンスルホネート（トシレート）、チオシアネート、およびトリフルオロメタンスルホネートからなる群から選択される陰イオンを含んでなる、請求項１、３、または５に記載の化合物の薬学的に許容可能な塩。
- トリフルオロアセテート、ホルメート、アセテート、プロピオネート、ブチレート、イソブチレート、ペンタノエート（バレレート）、イソペンタノエート、ヘキサノエート（カプロエート）、イソヘキサノエート、ヘプタノエート（エナンテート）、イソヘプタノエート、オクタノエート（カプリレート）、イソオクタノエート、ノナノエート（ペラルゴネート）、イソノナノエート、デカノエート（カプラート）、ラウレート、オレアート、パルミテート、ステアレート、ウンデシレネート、ベンゾエート、ニコチネート、ラクテート、グルクロネート、タルテート、マレート、スクシネート、フマレート、マロネート、タルテート、ヒドロキシスクシネート、２−オキソスクシネート、２−オキソグルタレート、アセトンジカルボキシレート、フタレート、オキサレート、アジペート、グルタレート、セバケート、マレエート、シトレート、エチレンジアミンテトラアセテート、アスパルテート、およびグルタメートからなる群から選択される陰イオンを含んでなる、請求項１、３、または５に記載の化合物の薬学的に許容可能な塩。
- 請求項１、３または５に記載の化合物と薬学的に許容可能な担体とを含んでなる、医薬組成物または美容組成物。
- 薬学的に許容可能な担体が局所投与用に処方される、請求項９に記載の医薬組成物。
- 組成物が軟膏、ローション、クリーム、マイクロエマルション、ゲル、オイル、および溶液から選択される形態である、請求項１０に記載の局所投与用医薬組成物。
- 抗炎症薬、鎮痛薬、抗菌薬、抗真菌薬、抗生剤、ビタミン、酸化防止剤、および日焼け止め剤から選択される付加的活性剤をさらに含んでなる、請求項１０に記載の局所投与用医薬組成物。
- 炎症、日光損傷、酸化ストレスまたは自然老化に関連するまたはそれらにより引き起こされる皮膚障害または疾患の処置の使用において皮膚または粘膜組織に適用するための、請求項１０に記載の医薬組成物。
- 対象の少なくとも１つの組織におけるＮＡＤレベルの上昇において使用するための、請求項１０に記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462008707P | 2014-06-06 | 2014-06-06 | |
| US62/008,707 | 2014-06-06 | ||
| PCT/IB2015/054281 WO2015186114A1 (en) | 2014-06-06 | 2015-06-05 | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516833A JP2017516833A (ja) | 2017-06-22 |
| JP2017516833A5 true JP2017516833A5 (ja) | 2018-07-12 |
| JP6559713B2 JP6559713B2 (ja) | 2019-08-14 |
Family
ID=53398163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016571240A Expired - Fee Related JP6559713B2 (ja) | 2014-06-06 | 2015-06-05 | ニコチンアミドリボシド類似体ならびにその医薬組成物および使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10485814B2 (ja) |
| EP (1) | EP3152220A1 (ja) |
| JP (1) | JP6559713B2 (ja) |
| KR (1) | KR20170008320A (ja) |
| CN (1) | CN106715455A (ja) |
| AU (1) | AU2015270090A1 (ja) |
| BR (1) | BR112016028672A2 (ja) |
| CA (1) | CA2951287A1 (ja) |
| MX (1) | MX2016016071A (ja) |
| RU (1) | RU2016149767A (ja) |
| WO (1) | WO2015186114A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7319744B2 (ja) | 2020-04-03 | 2023-08-02 | 深▲せん▼市迪克曼科技開発有限公司 | ニコチンアミドリボースの有機酸塩、その組成物及び製造方法 |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3174891T3 (pl) | 2014-07-24 | 2020-08-10 | W.R. Grace & Co. - Conn. | Krystaliczna postać rybozydu nikotynamidu |
| US10280190B2 (en) * | 2015-03-16 | 2019-05-07 | Chromadex, Inc. | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions |
| EP3288529A1 (en) * | 2015-05-01 | 2018-03-07 | The Procter and Gamble Company | Method of improving the appearance of skin and compositions therefor using nicotinamide riboside |
| AU2016274126A1 (en) | 2015-06-10 | 2018-01-18 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
| WO2017004102A1 (en) | 2015-06-29 | 2017-01-05 | The Procter & Gamble Company | Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container |
| WO2017011788A1 (en) | 2015-07-15 | 2017-01-19 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| US9855289B2 (en) | 2015-08-05 | 2018-01-02 | Metro International Biotech, Llc | Nicotinamide mononucleotide derivatives and their uses |
| EP3401323B1 (en) * | 2015-12-21 | 2020-07-08 | Showa Denko K.K. | Nicotinamide mononucleotide derivative and salt thereof, method for producing the same, topical agent, cosmetic and food additive |
| EP3236928B1 (en) | 2016-01-11 | 2020-12-09 | The Procter and Gamble Company | Method of treating a skin condition and compositions therefor |
| EP3429354A4 (en) | 2016-03-16 | 2020-03-25 | Chromadex Inc. | B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF AND METHOD FOR THE PRODUCTION THEREOF |
| NZ747693A (en) * | 2016-04-20 | 2023-07-28 | Chromadex Inc | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors |
| WO2018011634A1 (en) | 2016-07-15 | 2018-01-18 | Tarnava Alexander | Composition for producing hydrogen rich water and other products |
| GB2553001A (en) * | 2016-08-19 | 2018-02-21 | The Queen's Univ Of Belfast | Lactone intermediates of nicotinamide riboside and nicotinate riboside |
| CA3045876A1 (en) | 2016-11-11 | 2018-05-17 | The Queen's University Of Belfast | Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| US11633421B2 (en) | 2016-11-29 | 2023-04-25 | University Of Iowa Research Foundation | Use of NAD precursors for improving maternal health and/or offspring health |
| US20200121704A1 (en) * | 2017-01-13 | 2020-04-23 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating hypertension and arterial stiffness |
| CA3059228A1 (en) * | 2017-04-05 | 2018-10-11 | Cornell University | .beta.-nicotinate ester nucleotides and processes for preparing same |
| WO2018200357A1 (en) * | 2017-04-26 | 2018-11-01 | Elysium Health, Inc. | Methods and compositions of improving fertility |
| US20200179441A1 (en) * | 2017-04-27 | 2020-06-11 | H2 Water Technologies Ltd. | Synergistic compositions for increasing mitochondrial function and energy |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| EP3641725A1 (en) | 2017-06-23 | 2020-04-29 | The Procter and Gamble Company | Composition and method for improving the appearance of skin |
| US20200330497A1 (en) * | 2017-10-19 | 2020-10-22 | Elysium Health, Inc. | Prevention and treatment of tdp-43 associated diseases |
| US20200261483A1 (en) * | 2017-10-30 | 2020-08-20 | Elysium Health, Inc. | Methods and compositions for treating cystic fibrosis |
| US20210177875A1 (en) * | 2017-12-01 | 2021-06-17 | Elysium Health, Inc. | Methods and compositions for treating childhood or teen obesity |
| CA3140566A1 (en) * | 2018-05-15 | 2019-11-21 | Jumpstart Fertility Pty Ltd | Amino acid salts of nicotinic acid mononucleotide and nicotinamide mononucleotide as anti-ageing agents |
| JP2021525279A (ja) * | 2018-05-22 | 2021-09-24 | ジャンプスタート ファーティリティ ピーティーワイ リミテッド | 抗加齢剤としてのニコチン酸リボシドのアミノ酸塩 |
| CN112437657A (zh) | 2018-07-03 | 2021-03-02 | 宝洁公司 | 处理皮肤状况的方法 |
| CN108774278A (zh) * | 2018-09-10 | 2018-11-09 | 张洪喜 | 一种制备尼克酰胺核苷盐的方法 |
| US20210353617A1 (en) * | 2018-10-17 | 2021-11-18 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| WO2020131578A2 (en) * | 2018-12-17 | 2020-06-25 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| CN109674808A (zh) * | 2019-01-30 | 2019-04-26 | 四川大学 | β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途 |
| KR20220013540A (ko) * | 2019-02-21 | 2022-02-04 | 크로마덱스 아이엔씨. | 니코틴아미드 리보사이드, 니코틴산 리보사이드, 환원 니코티닐 리보사이드 화합물, 및 니코티닐 리보사이드 화합물 유도체의 제형에서의 용도 |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| WO2020206160A1 (en) * | 2019-04-05 | 2020-10-08 | Rejuvenation Therapeutics | Compositions comprising nicotinamide adenine dinucleotide-related compounds and use thereof |
| WO2020245191A1 (en) * | 2019-06-05 | 2020-12-10 | Société des Produits Nestlé S.A. | Reduced nicotinamideribosides for treating/preventing skeletal muscle disease |
| WO2020245190A1 (en) * | 2019-06-05 | 2020-12-10 | Société des Produits Nestlé S.A. | Reduced nicotinamideribosides for the treatment/prevention of liver disease |
| WO2020245187A1 (en) * | 2019-06-05 | 2020-12-10 | Société des Produits Nestlé S.A. | Reduced nicotinamideribosides for treating or preventing kidney disease |
| US20200397807A1 (en) * | 2019-06-18 | 2020-12-24 | MitoPower, LLC | Nicotinyl riboside compounds and their uses |
| JP2022544776A (ja) * | 2019-08-14 | 2022-10-21 | メトロ インターナショナル バイオテック，エルエルシー | ニコチンアミドアデニンジヌクレオチドの差次的モジュレーションのための化合物及び組成物 |
| FR3103702B1 (fr) * | 2019-11-28 | 2022-02-11 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes |
| CN110755432A (zh) * | 2019-12-02 | 2020-02-07 | 浙江大学 | 烟酰胺在制备治疗手足皮肤反应制剂中的应用 |
| FR3107897B1 (fr) * | 2020-03-06 | 2023-05-26 | Nuvamid Sa | Dérivés de nicotinamide mononucléotides |
| US20230114280A1 (en) * | 2020-03-09 | 2023-04-13 | Societe Des Produits Nestle S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions |
| US20230095103A1 (en) * | 2020-03-09 | 2023-03-30 | Societe Des Produits Nestle S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of lung diseases and conditions |
| WO2021180741A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions |
| EP4117677A1 (en) * | 2020-03-09 | 2023-01-18 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions |
| FR3108032B1 (fr) * | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes |
| FR3108031B1 (fr) * | 2020-03-12 | 2024-02-16 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes |
| AU2021260118A1 (en) * | 2020-04-24 | 2022-11-17 | Nuvamid Sa | Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus |
| EP3901160A1 (en) * | 2020-04-25 | 2021-10-27 | Nuvamid SA | Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus |
| US20210352902A1 (en) * | 2020-05-15 | 2021-11-18 | Psimos, Inc. | Composition for growth stimulation and resistance to stress factors for plants of the cannabaceae family |
| CN113768946A (zh) * | 2020-05-25 | 2021-12-10 | 南京帝昌医药科技有限公司 | 一种治疗糖尿病皮肤并发症的软膏及其制备方法 |
| US11583488B2 (en) | 2020-06-01 | 2023-02-21 | The Procter & Gamble Company | Method of improving penetration of a vitamin B3 compound into skin |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| US20230255994A1 (en) * | 2020-07-01 | 2023-08-17 | Metro International Biotech, Llc | Treatment of covid-19 and/or acute kidney injury |
| CN114053292A (zh) * | 2020-07-31 | 2022-02-18 | 高志玲 | 烟酰胺核苷芳甲酸酯类化合物及其组合物的用途以及化合物晶型 |
| WO2022029287A1 (en) * | 2020-08-07 | 2022-02-10 | Nuvamid Sa | Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of an antineoplastic-induced toxicity |
| WO2022077276A1 (zh) * | 2020-10-14 | 2022-04-21 | 音芙医药科技(上海)有限公司 | 烟酰胺单核苷酸与发酵乳杆菌联合在制备缓解皮肤光老化制剂中的应用 |
| RS65326B1 (sr) * | 2020-12-18 | 2024-04-30 | Nuvamid Sa | Derivati nikotinamid mononukleotida u lečenju i prevenciji bolesti srpastih ćelija |
| CA3219033A1 (en) | 2021-05-27 | 2022-12-01 | Metro International Biotech, Llc | Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use |
| CN113308436A (zh) * | 2021-06-24 | 2021-08-27 | 海南赛奥干细胞生物科技有限公司 | 一种人类骨髓、脐带血干细胞处理试剂盒及干细胞分离方法 |
| CN113398145B (zh) * | 2021-07-02 | 2022-10-14 | 合肥康诺生物制药有限公司 | 含nad与氨氯地平的药物组合物及其用途 |
| WO2023288195A1 (en) * | 2021-07-12 | 2023-01-19 | Cytokinetics, Inc. | Cd38 modulators and methods of use thereof |
| CN118139532A (zh) * | 2021-09-30 | 2024-06-04 | 雀巢产品有限公司 | 烟酰胺核糖核苷三油酸酯氯化物、含有这种化合物的组合物、以及制备和使用这种化合物的方法 |
| CN113817009B (zh) * | 2021-11-23 | 2022-06-03 | 中立安(北京)医药科技有限公司 | 烟酰胺单核苷类衍生物及其制备方法和应用 |
| CN115232184B (zh) * | 2021-12-06 | 2024-07-05 | 宁波熙健医药科技有限公司 | 呋喃核糖基吡啶衍生物及其药物组合物和用途 |
| CN115400140B (zh) * | 2022-01-27 | 2024-02-20 | 宁波熙健医药科技有限公司 | 呋喃核糖基吡啶衍生物用于预防或治疗癫痫或惊厥的用途 |
| WO2023154844A2 (en) * | 2022-02-10 | 2023-08-17 | Workman David Henry | Compositions comprising nad+ and associated methods of treatment |
| WO2024123296A1 (en) * | 2022-12-07 | 2024-06-13 | Atatürk Üni̇versi̇tesi̇ Rektörlüğü Bi̇li̇msel Araştirma Projeleri̇ (Bap) Koordi̇nasyon Bi̇ri̇mi̇ | A compound containing nicotinamide riboside to inhibit cyst formation and induce ovulation in polycystic ovary syndrome |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2798076A (en) | 1952-03-14 | 1957-07-02 | Hoffmann La Roche | 1-isonicotinyl-2-hydroxyalkylhydrazines |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| RU2188828C2 (ru) | 1996-10-16 | 2002-09-10 | Ай-Си-Эн Фармасьютикалз, Инк. | Моноциклические l-нуклеозиды, их аналоги и применения |
| TWI257303B (en) | 1998-12-01 | 2006-07-01 | Univ Kentucky Res Found | A method for enhancing protective cellular responses to genotoxic stress in skin |
| WO2000032194A2 (en) | 1998-12-01 | 2000-06-08 | University Of Kentucky Research Foundation | Use of niacin for the prevention of photocarcinogenesis and photoimmunosuppression |
| US6288089B1 (en) | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
| CA2441461C (en) | 2000-04-14 | 2007-07-10 | Niadyne Corporation | Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia |
| US6689760B1 (en) | 2000-07-10 | 2004-02-10 | Enzrel Inc. | Anti-mycobacterial compositions |
| CA2421269A1 (en) | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US20050096256A1 (en) | 2003-07-01 | 2005-05-05 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US20050227327A1 (en) | 2004-02-10 | 2005-10-13 | Brenner Charles M | Nicotinamide riboside kinase compositions and methods for using the same |
| CA2555675A1 (en) | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
| US8114626B2 (en) | 2004-02-10 | 2012-02-14 | Trustees Of Dartmouth College | Yeast strain and method for using the same to produce nicotinamide riboside |
| DK1755391T3 (en) | 2004-06-04 | 2016-02-08 | Univ Washington | METHODS AND COMPOSITIONS FOR THE TREATMENT OF neuropathies |
| EP2805719A1 (en) * | 2005-03-30 | 2014-11-26 | Glaxosmithkline LLC | Nicotinamide riboside and analogues thereof |
| AU2006278397B2 (en) | 2005-08-04 | 2013-01-17 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| EP3730507A1 (en) | 2005-11-18 | 2020-10-28 | Cornell Research Foundation, Inc. | Nicotinoyl riboside and nicotinamide riboside compositions for use in reducing toxicity induced by hmg-coa reductase inhibitors |
| US20120135091A1 (en) | 2007-01-18 | 2012-05-31 | Roth Mark B | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
| MX2009008022A (es) | 2007-01-26 | 2009-12-11 | Univ Washington | Metodos y composiciones para tratar neuropatias. |
| CL2008001821A1 (es) | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
| TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| CN102083438B (zh) | 2008-05-01 | 2016-11-09 | 西特里斯药业公司 | 作为沉默信息调节因子的调节剂的喹啉和相关类似物 |
| CA2729128C (en) | 2008-07-03 | 2016-05-31 | Sirtris Pharmaceuticals, Inc. | Benzimidazoles and related analogs as sirtuin modulators |
| WO2010011111A2 (ko) | 2008-07-25 | 2010-01-28 | 서울대학교산학협력단 | 뎁손을 유효성분으로 함유하는 노화조절용 및/또는 수명연장용 조성물 |
| AU2009295946B2 (en) | 2008-09-29 | 2013-03-21 | Sirtris Pharmaceuticals, Inc. | Chromenone analogs as sirtuin modulators |
| SG171835A1 (en) | 2008-12-19 | 2011-07-28 | Sirtris Pharmaceuticals Inc | Thiazolopyridine sirtuin modulating compounds |
| JP2013509442A (ja) | 2009-10-29 | 2013-03-14 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン調節因子としての二環式ピリジンおよび類似体 |
| WO2011081942A1 (en) | 2009-12-14 | 2011-07-07 | Cornell University | Activation and activators of sirt5 |
| WO2012094343A1 (en) | 2011-01-05 | 2012-07-12 | Trilink Biotechnologies | Chemically substituted thermosensitive probes and cofactors for hot start ligation |
| WO2012114204A2 (en) | 2011-02-15 | 2012-08-30 | Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto | Methods of treating mitochondrial dysfunction |
| WO2012125900A1 (en) | 2011-03-16 | 2012-09-20 | Enanta Pharmaceuticals, Inc. | 2'-allene-substituted nucleoside derivatives |
| WO2013044030A1 (en) | 2011-09-23 | 2013-03-28 | Enanta Pharmaceuticals, Inc. | 2'-chloroacetylenyl substituted nucleoside derivatives |
| CN104394869A (zh) | 2011-10-20 | 2015-03-04 | 葛兰素史密斯克莱有限责任公司 | 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物 |
| AU2012325916A1 (en) | 2011-10-20 | 2014-05-01 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| KR20140077964A (ko) | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
| JP6289460B2 (ja) | 2012-07-16 | 2018-03-07 | コーネル ユニヴァーシティー | 難聴を治療するためのニコチンアミドリボシド |
| GB201313465D0 (en) * | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| JP6509844B2 (ja) | 2013-10-30 | 2019-05-08 | クロマデックス, インコーポレイテッドChromaDex, Inc. | 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物 |
-
2015
- 2015-06-05 US US15/315,160 patent/US10485814B2/en active Active
- 2015-06-05 KR KR1020177000145A patent/KR20170008320A/ko unknown
- 2015-06-05 JP JP2016571240A patent/JP6559713B2/ja not_active Expired - Fee Related
- 2015-06-05 AU AU2015270090A patent/AU2015270090A1/en not_active Abandoned
- 2015-06-05 CN CN201580041352.4A patent/CN106715455A/zh active Pending
- 2015-06-05 RU RU2016149767A patent/RU2016149767A/ru unknown
- 2015-06-05 BR BR112016028672A patent/BR112016028672A2/pt not_active Application Discontinuation
- 2015-06-05 CA CA2951287A patent/CA2951287A1/en not_active Abandoned
- 2015-06-05 EP EP15729244.2A patent/EP3152220A1/en not_active Withdrawn
- 2015-06-05 MX MX2016016071A patent/MX2016016071A/es unknown
- 2015-06-05 WO PCT/IB2015/054281 patent/WO2015186114A1/en active Application Filing
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7319744B2 (ja) | 2020-04-03 | 2023-08-02 | 深▲せん▼市迪克曼科技開発有限公司 | ニコチンアミドリボースの有機酸塩、その組成物及び製造方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516833A5 (ja) | ||
| RU2016149767A (ru) | Аналоги никотинамидрибозида и фармацевтические композиции и их применение | |
| AU2003240441B2 (en) | Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives | |
| JP2019031561A (ja) | 抗菌薬の組成物および製剤、その製造法および微生物感染症の治療方法 | |
| JP6767265B2 (ja) | 抵抗性ざ瘡のための処置の方法 | |
| CA2995794A1 (en) | Tetracycline management of egfr inhibitor associated dermatoses | |
| JP2009500336A (ja) | 局所用皮膚治療組成物 | |
| JP2002212053A (ja) | ビタミンｂ３化合物による皮膚外観の調整方法 | |
| JP6271527B2 (ja) | レチノイドを含有する油／水エマルション型局所的組成物 | |
| US20190307778A1 (en) | Tetracycline management of egfr inhibitor associated dermatoses | |
| AU2012304407A1 (en) | Topical itraconazole formulations and uses thereof | |
| CN103347507A (zh) | 用于治疗痤疮的褪黑激素以及抗微生物剂或抗菌剂 | |
| EP1147086A1 (en) | Compositions for the treatment of skin diseases | |
| JP2018052916A (ja) | 外用組成物 | |
| KR20150028251A (ko) | 특별한 가용화된 레티노이드를 함유하는 겔 형태의 국소 조성물 | |
| JP7067581B2 (ja) | ローション剤 | |
| JP2595036B2 (ja) | 第４級アンモニウムレチノエートおよびこれを含む組成物 | |
| JP2021004184A (ja) | アラントイン及び／又はその誘導体の安定化方法 | |
| KR20130025768A (ko) | 피부 미백 효과를 나타내는 신규 코지산 유도체 | |
| CA1113460A (en) | Zinc erythromycin | |
| JP2017186329A (ja) | 皮膚色素沈着抑制剤 | |
| JP2019011301A (ja) | 口腔用組成物 | |
| US10653659B2 (en) | Compositions comprising a compound from the family of avermectins and an agonist compound for at least one of the retinoic acid receptors for treating acne | |
| JP7467037B2 (ja) | 外用組成物 | |
| JP2002506804A (ja) | スキンケア組成物 |